Freedom of Information request on COVID-19 vaccines fatal ADRs
Published 28 May 2021
© Crown copyright 2021
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-26-april-2021/freedom-of-information-request-on-covid-19-vaccines-fatal-adrs
27th April 2021 FOI 21/321
Dear
Thank you for your email dated 31st March 2021, where you asked for the following information: “the total number of deaths for any reason within 28 days of anyone, who has received a covid vaccine from the start of the vaccination roll out to date”
Suspected adverse drug reactions can be reported via the Yellow Card scheme at any time after the side effect has occurred. Additionally, the time frame from when the patient received the vaccine to experiencing a suspected side effect is not always provided by the reporter. We review all reports of death regardless of the time to onset from receiving a medicine or vaccine. Our routine ADR summary publication provides information on all reports received associated with COVID-19 vaccines including fatalities. https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions We follow-up all fatalities where permission has been provided to do so for further information including post-mortem details if available. As with any serious suspected ADR, reports with a fatal outcome are fully evaluated by the MHRA, to consider whether the vaccine (or medicine) may have caused the event, or whether the event and fatal outcome were likely to be purely coincidental and due to underlying illness.
I hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.
Yours sincerely, FOI Team Vigilance and Risk Management of Medicines Division